Clinical trials
Patient Safety clinical trials
Below are recruiting patient safety clinical trials, each written for real people, not researchers. We’re tracking 1,356 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06892548RecruitingPhase 1/Phase 2
Combination therapy for advanced lung cancer
This trial tests a new combination of two investigational drugs, BNT324 and BNT327, for people with advanced lung cancer that cannot be removed by surgery. It aims to see if the combination is safe and effective for different types of lung cancer, including non-small cell and small cell lung cancer.
Phoenix, ArizonaAges 18 years+ - NCT07287033RecruitingPhase 1
Safety study of MY006 in healthy people and people with peanut allergy
This early-phase study tests a new investigational medication (MY006) to see if it is safe and how the body processes it. It is given to both healthy volunteers and people with peanut allergy. The goal is to gather safety information before larger trials.
Little Rock, ArkansasAges 12–55 - NCT04271956RecruitingPhase 2
Study drugs for Richter transformation in CLL
This Phase 2 study tests zanubrutinib plus tislelizumab, with or without sonrotoclax, for people whose CLL has changed into Richter transformation (an aggressive lymphoma). It aims to improve anti-cancer response while tracking side effects and safety.
ViennaAges 18 years+ - NCT06303505RecruitingPhase 1/Phase 2
Study of TUB-040 for ovarian and lung cancer
This study tests a new drug called TUB-040 that targets a protein (NaPi2b) found on some ovarian and lung cancer cells. It is for people whose cancer has stopped responding to standard treatments and who have not had certain lung problems in the past.
Birmingham, AlabamaAges 18 years+ - NCT07549321RecruitingPhase 2/Phase 3
Hu14 Immunotherapy for High-Risk Neuroblastoma in Children
This study tests a new antibody-based immunotherapy called hu14 for children and young adults with high-risk neuroblastoma (an aggressive childhood cancer that has spread). The treatment is designed to help the immune system fight cancer cells.
Aurora, ColoradoAges 1.5 years–18 years - NCT06688435RecruitingPhase 1
Immune cell therapy for hard-to-treat myasthenia gravis
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
JinanAges 18–65 - NCT07583251RecruitingPhase 1
Safety of a supplement for mild memory loss
This trial tests an oral supplement called gamma glutamylcysteine (GGC) in people with mild cognitive impairment (MCI) to see if it is safe and well-tolerated. It may help by supporting the body's natural defenses against cell damage.
Pittsburgh, PennsylvaniaAges 55–80 - NCT07199738Recruiting
Knee replacement study with a new implant option
This study tests a specific knee implant insert (LEGION Medial Stabilized) in people who need a total knee replacement due to arthritis or similar joint disease. It aims to see if the device is safe and works well over time.
Newton, MassachusettsAges 18–80 - NCT06834139Enrolling by invitation
Testing a new cleaning device for people with braces
This trial tests a device called the Neo Pill to see if it helps keep teeth clean for people with braces. It compares the device to regular brushing and may help reduce plaque and gum problems during orthodontic treatment.
Kragujevac, SerbiaAges 18 years+ - NCT06378242RecruitingPhase 1/Phase 2
Testing a bladder cancer drug for high-risk NMIBC patients
This trial tests a drug called Disitamab Vedotin, given directly into the bladder, for a type of early bladder cancer (high-risk NMIBC) that has a protein called HER2. It aims to see if this treatment can help avoid more radical surgery.
Guangzhou, GuangdongAges 18–75 - NCT06272500Recruiting
Betaine for high gastrin in autoimmune gastritis
This trial tests if betaine hydrochloride can lower high gastrin levels caused by autoimmune gastritis. It may help people with this condition by reducing stomach-related symptoms.
Zhengzhou, HenanAges Any age - NCT06075420Recruiting
Shorter blood thinner use after GENOSS stent in heart disease
This trial tests whether a shorter course of dual antiplatelet therapy (two blood thinners) is safe and effective for people who have received a GENOSS stent for coronary artery disease. It aims to reduce the risk of bleeding while still preventing heart attacks.
Wŏnju, Gangwon StateAges 19 years+ - NCT04724603Recruiting
Review of side effects after phage treatment for bone infections
This study looks back at people who were treated with phage therapy for a bone, joint, or implant infection and later had a side effect. It aims to better understand how safe phage therapy is in real-life use.
LyonAges Any age - NCT05823285RecruitingPhase 1
Study of QLS31903 for advanced solid tumors
This Phase 1 trial tests the safety and how the medicine works in the body, and also looks at early signs of effectiveness. It is for adults with advanced solid tumors, and for Phase 1b specifically, the tumor must show a marker called GPC3.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07231120RecruitingPhase 1
Testing SXRN injection for cancer-related weight loss
This trial tests a new injection called SXRN for people with advanced cancer who have lost weight and appetite (cancer cachexia). The goal is to see if it is safe and might help improve weight and appetite.
Beijing, Beijing MunicipalityAges 18–75 - NCT05872347RecruitingPhase 2
Brain metastasis breast cancer trial with hormone therapy plus SPH4336
This trial tests whether SPH4336, added to standard hormone (endocrine) therapy, can improve outcomes for people with breast cancer that has spread to the brain. It also looks closely at safety and side effects.
Hefei, AnhuiAges 18–75 - NCT07225751Recruiting
MagnetOs Bone Graft vs. Your Own Bone for Foot Fusion
This study tests a new bone graft material (MagnetOs) against using your own bone for hindfoot or ankle fusion surgery. The goal is to see if the new material works just as well for helping bones heal together.
Vail, ColoradoAges 18–75 - NCT07514169RecruitingPhase 2
New Combination Drug for Older Adults with B-Cell Lymphoma
This study tests whether a new three-drug combination (Pola-ZR-Glo) works safely and effectively for older adults with a type of blood cancer called large B-cell lymphoma who cannot or prefer not to receive standard chemotherapy. The goal is to find a gentler treatment option for frail or elderly patients.
ShanghaiAges 70 years+ - NCT04142437Recruiting
Tracking how larotrectinib works for NTRK fusion cancers in routine care
This study follows people with cancers that have an NTRK gene fusion to learn how safe and effective larotrectinib is during everyday treatment. It may help confirm whether this medicine works well in real-world patients and side effects stay manageable.
Mesa, ArizonaAges Any age - NCT07266116RecruitingPhase 1/Phase 2
TQB2934 injection for light chain amyloidosis
This trial tests a new injectable drug called TQB2934 for people with systemic light chain amyloidosis. It aims to see if the drug is safe and effective for those whose disease has come back or gotten worse after previous treatment.
Beijing, Beijing MunicipalityAges 18–80 - NCT06911489RecruitingPhase 1
Safety trial of a new targeted therapy for advanced solid tumors
This trial tests a new drug, NRT6020, that targets a protein called FAP found on many solid tumors. It aims to see if the drug is safe and how it works in people with advanced solid tumors that have not responded to other treatments.
ShanghaiAges 18–80 - NCT06992661RecruitingPhase 1
Inhaled RJ026 study for interstitial lung disease patients
This trial tests a single inhaled dose of RJ026 in patients with interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF) or connective tissue disease-related ILD (CTD-ILD). It helps see how the drug moves through the body and if it's safe.
Shanghai, Shanghai MunicipalityAges 40 years+ - NCT03671044RecruitingPhase 3
Testing a nano-form of docetaxel for triple-negative breast cancer
This Phase 3 study tests whether a special form of docetaxel (a chemotherapy drug) works better and is safe for people with triple-negative breast cancer that has spread or grown locally. You may be eligible if your cancer is triple-negative and you have measurable disease that can be tracked on scans, along with adequate organ and heart function.
Columbus, GeorgiaAges 18–65 - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
La Jolla, CaliforniaAges 18 years+
Hear when a new Patient Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for patient safety?
- Yes. Clin2 currently lists 1,356 recruiting patient safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a patient safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a patient safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.